Cytosorbents Corp has demonstrated significant revenue growth over recent years fueled by its proprietary polymer technology, but persistent operating losses reflect ongoing R&D investment and regulatory challenges. The company’s DrugSorb-ATR device encountered an FDA De Novo application denial in April 2025, followed by an appeal process and plans for a resubmission with new real-world data expected mid-2026. Despite these regulatory hurdles and market acceptance risks, Cytosorbents retains a strong liquidity position with a current ratio above 2, though negative cash flows continue. Capital allocation remains conservative with no dividends or buybacks, focusing on funding clinical and regulatory milestones.